Ablynx, of Ghent, Belgium, appointed Wim Ottevaere chief financial officer.
Advanced Life Sciences Holdings Inc., of Woodridge, Ill., appointed Terry Osborn and Israel Rubenstein to its board.
Advanced Viral Research Corp., of Yonkers, N.Y., appointed Stephen Elliston president, CEO and member of its board.
Affymax Inc., of Palo Alto, Calif., appointed John Walker to its board.
Allion Healthcare Inc., of Melville, N.Y., appointed Russell Fichera an independent nonexecutive director who will serve on the audit committee.
Amarin Corp. plc, of London, formed a scientific advisory board consisting of John Climax, Jan Wallace, Reid Patterson, Mark Pierce and Mehar Manku.
Amazon Biotech Inc., of New York, appointed Evan Bental regulatory assistant.
Ambrilia Biopharma Inc., of Montreal, appointed Joseph Krivulka and Stephen Sudovar to its board.
Ambrx Inc., of San Diego, appointed Hazel Aker senior vice president of operations and business affairs.
Astex Therapeutics, of Cambridge, UK, appointed Leon Bushara CEO.
Athenagen Inc., of South San Francisco, appointed John Donovan chief financial officer.
AtheroGenics Inc., of Atlanta, promoted Mark Colonnese executive vice president, commercial operations; Rob Scott executive vice president, research and development; and Charles Montgomery senior vice president, business development and alliance management.
Avecia Holdings plc, of Tees Valley, UK, appointed to its board CEO Adrian Buckmaster, Chief Financial Officer Duncan McLellan and president of the Avecia Biologics business unit Kevin Cox.